108 research outputs found

    Atmosphere-Ionosphere Response to the M9 Tohoku Earthquake Revealed by Joined Satellite and Ground Observations. Preliminary results

    Get PDF
    The recent M9 Tohoku Japan earthquake of March 11, 2011 was the largest recorded earthquake ever to hit this nation. We retrospectively analyzed the temporal and spatial variations of four different physical parameters - outgoing long wave radiation (OLR), GPS/TEC, Low-Earth orbit tomography and critical frequency foF2. These changes characterize the state of the atmosphere and ionosphere several days before the onset of this earthquake. Our first results show that on March 8th a rapid increase of emitted infrared radiation was observed from the satellite data and an anomaly developed near the epicenter. The GPS/TEC data indicate an increase and variation in electron density reaching a maximum value on March 8. Starting on this day in the lower ionospheric there was also confirmed an abnormal TEC variation over the epicenter. From March 3-11 a large increase in electron concentration was recorded at all four Japanese ground based ionosondes, which return to normal after the main earthquake. We found a positive correlation between the atmospheric and ionospheric anomalies and the Tohoku earthquake. This study may lead to a better understanding of the response of the atmosphere /ionosphere to the Great Tohoku earthquakeComment: Preliminary results reported at EGU 2011 in Vienna, Austri

    In situ study of the temperature stability of TiO1.05 titanium monooxide using synchrotron radiation

    Full text link
    The temperature stability of cubic TiO1.05 titanium monooxide is investigated. An in situ X-ray structural analysis is performed using synchrotron radiation in a high temperature vacuum chamber. It is found that under poor vacuum and at high heating rates of up to 1250 C, the structural transformations in TiO1.05 occur at 630 C. In particular, there is a phase transition from TiO1.05 (space group Fm-3m) to rhombohedraic Ti2O3 (space group R-3c) via Ti2.5O3 (space group Immm). Β© 2013 Allerton Press, Inc

    Synthesis of octahydro-2H-chromen-4-ol from vanillin and isopulegol over acid modified montmorillonite clays: Effect of acidity on the Prins cyclization

    Get PDF
    Two calcium-rich natural layered aluminosilicates containing 90–95 wt.% montmorillonite were chemically activated using 0.125–3.0 M HCl solutions. Structural and textural properties were characterized by X-ray diffraction, elemental analysis and N2-adsorption/desorption analyses. According to infrared spectroscopy using pyridine as probe molecule, the amount of BrΓΈnsted acid sites increased when increasing HCl concentration. The catalytic performance of these materials was investigated in the Prins cyclization of (βˆ’)-isopulegol with vanillin to form octahydro-2H-chromen-4-ol, carried out in toluene at 35 Β°C. It was found that the amount of BrΓΈnsted acid sites and the microporosity of the catalysts are key factors for the control of the reaction rate and the selectivity towards octahydro-2H-chromen-4-o

    Determination of Debye Temperatures and Lamb-MΓΆssbauer Factors for LnFeO3 Orthoferrite Perovskites (Ln = La, Nd, Sm, Eu, Gd)

    Get PDF
    Lanthanide orthoferrites have wide-ranging industrial uses including solar, catalytic and electronic applications. Here a series of lanthanide orthoferrite perovskites, LnFeO3 (Ln = La; Nd; Sm; Eu; Gd), prepared through a standard stoichiometric wet ball milling route using oxide precursors, has been studied. Characterisation through X-ray diffraction and X-ray fluorescence confirmed the synthesis of phase-pure or near-pure LnFeO3 compounds. 57Fe MΓΆssbauer spectroscopy was performed over a temperature range of 10 K to 293 K to observe hyperfine structure and to enable calculation of the recoil-free fraction and Debye temperature (ΞΈD) of each orthoferrite. Debye temperatures (Ln = La 474 K; Nd 459 K; Sm 457 K; Eu 452 K; Gd 473 K) and recoil-free fractions (Ln = La 0.827; Nd 0.817; Sm 0.816; Eu 0.812; Gd 0.826) were approximated through minimising the difference in the temperature dependent experimental Centre Shift (CS) and theoretical Isomer Shift (IS), by allowing the Debye temperature and Isomer Shift values to vary. This method of minimising the difference between theoretical and actual values yields Debye temperatures consistent with results from other studies determined through thermal analysis methods. This displays the ability of variable-temperature MΓΆssbauer spectroscopy to approximate Debye temperatures and recoil-free fractions, whilst observing temperature induced transitions over the temperature range observed. X-ray diffraction and Rietveld refinement show an inverse relationship between FeO6 octahedral volume and approximated Debye temperatures. Raman spectroscopy show an increase in the band positions attributed to soft modes of Ag symmetry, Ag(3) and Ag(5) from La to GdFeO3 corresponding to octahedral rotations and tilts in the [010] and [101] planes respectively

    Choice of the optimal treatment strategy for patient with multifocal bladder cancer: clinical case

    Get PDF
    Transurethral resection of bladder is the standard surgical procedure for management of bladder cancer when it is suspected. Accurate clinical staging of the disease based on the histologic findings followed by further assessment of recurrence risks and risks of disease progression are vital for defining an optimal individualized treatment strategy. Early radical cystectomy (RC) is recommended for patients suffering from superficial bladder cancer at high risk for tumor recurrence.Patients diagnosed with bladder tumors with multifocal lesions as well as with tumor size > 3 сm are related to a group of high risk for cancer progression. In this case in order to take a decision about the benefits of radical surgery, it’s essential to remember that RC is considered to be a major surgical procedure with a broad range of both intraoperative and postoperative complications. The vast majority of patients experience a lower quality of life based on the development of different types of metabolic alterations as well as the necessity for using urinals or inability to have adequate urination control. Organ-preserving therapy with active follow-up is thereby preferably to conduct on young patients with active life position.In our clinical case we confirmed that such treatment strategy allows to establish adequate control over neoplastic process with less negative impact on patients’ quality of life

    POLYPOID CYSTITIS: A FINDING AND DIFFERENTIAL DIAGNOSIS

    Get PDF
    Background. Polypoid cystitis may simulate urothelial neoplasias cystoscopically and histologically. The frequency of polypoid cystitis is 0.38%; that among patients undergoing bladder catheterization is 6 %.Subjects and methods. The authors estimated the frequency of polypoid cystitis among chronic cystitis patients admitted to City Clinical Hospital Fifty, a base of the Clinic of Urology, Moscow State University of Medicine and Dentistry, in the period from February 2008 to February 2010. Out of 819 patients followed up, 3 who had diagnosed as having polypoid cystitis complained of pollakiuria, imperative micturate urges, and macrohematuria. They underwent ultrasonography, computed tomography, and cystoscopy; bladder masses measured 1.0, 7.0, and 11.5 cm, respectively; extensive growth was verified in 2 cases. Endoscopic studies identified procumbent rough-villous masses without well-defined outlines with the signs of bullous edema, decay, hemorrhages, and urinary salt encrustations. By taking into account the clinical picture and laboratory and instrumental findings, the authors suspected stage T3bNΡ…MΡ… bladder tumor in 2 patients and T1NΡ…MΡ… stage in 1. According to the European Association of Urology guidelines for management of bladder cancer, the patients underwent transurethral bladder resection. The patients were diagnosed as having polypoid cystitis on the basis of postmortem evidence.Results. In this study the frequency of polypoid cystitis was 37 %. Polypoid cystitis, a benign mass without a risk for malignancy, had signs of invasive transitional cell carcinoma.Conclusion. Such cases that rarely occur in practice are of clinical value and interest to urologists, pathologists, and oncologists.</p

    НовоС Π² стадировании ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΡ‹ ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря

    Get PDF
    Β Introduction. Histological grading system is an important prognostic factor of bladder cancer. Grading of urothelial carcinoma has been a matter of debate since the three-grade system was introduced in 1973.Objective. Optimization of the grading system for urothelial carcinoma.Materials and methods. An analysis of literature devoted to evaluation of diagnostic significance, variability and interobserver reproducibility of the existing classifications of urothelial cancer of the bladder proposed in 1973, 1998, 1999 and 2004.Results. The classification proposed in 1973 is the most popular and time honored method of grading bladder tumors. In 1998 it was modified by the International Society of Urological Pathology. In 1999 the World Health Organization (WHO) approved a new classification which preserved the three-grade system but differed from the previous ones. According to this new classification, tumors could fall into the following categories: papilloma, papillary urothelial neoplasm of low malignant potential, urothelial carcinoma of I, II, and III malignancy grade. The definition of papilloma was identical in all of these classifications. In 2004 a new WHO classification was introduced in which non-invasive urothelial tumors were subdivided into papilloma, papillary urothelial neoplasm of low malignant potential and low and high grade carcinoma. All of the proposed grading systems had a certain level of subjectivity and interobserver reproducibility, but reproducibility between unfamiliar pathologists was considerably higher than in groups of pathologists who had studied or worked together. Importantly, the 2004 WHO classification aimed to provide a detailed explanation of histological criteria for each diagnostic category and therefore improve reproducibility between different pathologists. However, no improvement of reproducibility in comparison with the 1973 WHO classification was observed. Moreover, among the pathologists better reproducibility of the 1973 WHO classification was registered compared to the 1999 and 2004 classifications. Reproducibility of the papillary urothelial neoplasm of low malignant potential diagnosis was only 48 %. At the same time, reproducibility of the 1973 WHO classification too has its problems. The biggest criticism is ambiguity in the diagnostic criteria of the 3 grades of urothelial carcinoma.Conclusions. Standardization of the grading system of superficial bladder cancer allows to validate comparison between treatment outcomes in different centers. Introduction of the 2004 classification is the first step to treatment and monitoring standardization, but all of the classifications proposed by the WHO have shortcomings caused by considerable heterogeneity of papillary urothelial neoplasms. Significant interobserver reproducibility between papillary urothelial neoplasm of low malignant potential and low grade papillary urothelial carcinoma shows inadvisability of creating a separate diagnostic category for papillary urothelial neoplasm of low malignant potential.Β Π’Π²Π΅Π΄Π΅Π½ΠΈΠ΅. ГистологичСская систСма стадирования – Π²Π°ΠΆΠ½Ρ‹ΠΉ прогностичСский Ρ„Π°ΠΊΡ‚ΠΎΡ€ Ρ€Π°ΠΊΠ° ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря. Π‘Ρ‚Π°Π΄ΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠ΅ ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΡ‹ ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря являСтся ΠΏΡ€Π΅Π΄ΠΌΠ΅Ρ‚ΠΎΠΌ дискуссий с ΠΌΠΎΠΌΠ΅Π½Ρ‚Π° внСдрСния Π² 1973 Π³. трСхступСнчатой систСмы.ЦСль исслСдования – ΠΎΠΏΡ‚ΠΈΠΌΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Ρ‚ΡŒ Π³ΠΈΡΡ‚ΠΎΠ»ΠΎΠ³ΠΈΡ‡Π΅ΡΠΊΡƒΡŽ систСму стадирования ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΡ‹.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. ΠŸΡ€ΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· Π»ΠΈΡ‚Π΅Ρ€Π°Ρ‚ΡƒΡ€Ρ‹, посвящСнный ΠΎΡ†Π΅Π½ΠΊΠ΅ диагностичСской значимости, Π²Π°Ρ€ΠΈΠ°Π±Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΠΈ ΠΈ ΠΌΠ΅ΠΆ- Π½Π°Π±Π»ΡŽΠ΄Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ воспроизводимости ΠΈΠΌΠ΅ΡŽΡ‰ΠΈΡ…ΡΡ Π½Π° сСгодняшний дСнь классификаций ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½ΠΎΠ³ΠΎ Ρ€Π°ΠΊΠ° ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря: 1973, 1998, 1999 ΠΈ 2004 Π³Π³.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. ΠŸΡ€Π΅Π΄Π»ΠΎΠΆΠ΅Π½Π½Π°Ρ Π² 1973 Π³. классификация – Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ распространСнный ΠΈ ΠΏΡ€ΠΎΠ²Π΅Ρ€Π΅Π½Π½Ρ‹ΠΉ Π²Ρ€Π΅ΠΌΠ΅Π½Π΅ΠΌ ΠΌΠ΅Ρ‚ΠΎΠ΄ стадирования ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря. Π’ 1998 Π³. ΠΎΠ½Π° Π±Ρ‹Π»Π° ΠΌΠΎΠ΄ΠΈΡ„ΠΈΡ†ΠΈΡ€ΠΎΠ²Π°Π½Π° ΠœΠ΅ΠΆΠ΄ΡƒΠ½Π°Ρ€ΠΎΠ΄Π½Ρ‹ΠΌ общСством урологичСской ΠΏΠ°Ρ‚ΠΎΠ»ΠΎΠ³ΠΈΠΈ. Π’ 1999 Π³. ВсСмирная организация здравоохранСния (Π’ΠžΠ—) ΡƒΡ‚Π²Π΅Ρ€Π΄ΠΈΠ»Π° Π½ΠΎΠ²ΡƒΡŽ ΠΊΠ»Π°ΡΡΠΈΡ„ΠΈΠΊΠ°Ρ†ΠΈΡŽ, которая ΠΎΡΡ‚Π°Π»Π°ΡΡŒ трСхступСнчатой, Π½ΠΎ ΠΎΡ‚Π»ΠΈΡ‡Π°Π»Π°ΡΡŒ ΠΎΡ‚ Ρ€Π°Π½Π΅Π΅ ΠΏΡ€Π΅Π΄Π»ΠΎΠΆΠ΅Π½Π½Ρ‹Ρ… Ρ‚Π΅ΠΌ, Ρ‡Ρ‚ΠΎ ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ ΠΏΠΎΠ΄Ρ€Π°Π·Π΄Π΅Π»ΡΠ»ΠΈΡΡŒ Π½Π° ΠΏΠ°ΠΏΠΈΠ»Π»ΠΎΠΌΡƒ, ΠΏΠ°ΠΏΠΈΠ»Π»ΡΡ€Π½ΡƒΡŽ ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½ΡƒΡŽ ΠΎΠΏΡƒΡ…ΠΎΠ»ΡŒ с Π½ΠΈΠ·ΠΊΠΈΠΌ ΠΏΠΎΡ‚Π΅Π½Ρ†ΠΈΠ°Π»ΠΎΠΌ злокачСствСнности, ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½ΡƒΡŽ ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΡƒ I, II ΠΈ III стСпСнСй злокачСствСнности. ΠžΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠ°ΠΏΠΈΠ»Π»ΠΎΠΌΡ‹ Π±Ρ‹Π»ΠΎ ΠΎΠ΄ΠΈΠ½Π°ΠΊΠΎΠ²Ρ‹ΠΌ Π²ΠΎ всСх этих классификациях. Π’ 2004 Π³. ΡƒΡ‚Π²Π΅Ρ€ΠΆΠ΄Π΅Π½Π° новая классификация Π’ΠžΠ—, Π² ΠΊΠΎΡ‚ΠΎΡ€ΠΎΠΉ Π½Π΅ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½Ρ‹Π΅ ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒ- Π½Ρ‹Π΅ ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ ΠΏΠΎΠ΄Ρ€Π°Π·Π΄Π΅Π»ΡΡŽΡ‚ΡΡ Π½Π° ΠΏΠ°ΠΏΠΈΠ»Π»ΠΎΠΌΡƒ, ΠΏΠ°ΠΏΠΈΠ»Π»ΡΡ€Π½ΡƒΡŽ ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½ΡƒΡŽ ΠΎΠΏΡƒΡ…ΠΎΠ»ΡŒ с Π½ΠΈΠ·ΠΊΠΈΠΌ ΠΏΠΎΡ‚Π΅Π½Ρ†ΠΈΠ°Π»ΠΎΠΌ злокачСствСнности, ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΡƒ Π½ΠΈΠ·ΠΊΠΎΠΉ ΠΈ высокой стСпСнСй злокачСствСнности. ВсС ΠΏΡ€Π΅Π΄Π»ΠΎΠΆΠ΅Π½Π½Ρ‹Π΅ систСмы Π³Ρ€Π°Π΄Π°Ρ†ΠΈΠΈ ΠΈΠΌΠ΅Π»ΠΈ Ρ‚Ρƒ ΠΈΠ»ΠΈ ΠΈΠ½ΡƒΡŽ ΡΡ‚Π΅ΠΏΠ΅Π½ΡŒ ΡΡƒΠ±ΡŠΠ΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΠΈ ΠΈ ΠΌΠ΅ΠΆΠ½Π°Π±Π»ΡŽΠ΄Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ воспроизводимости, ΠΎΠ΄Π½Π°ΠΊΠΎ Π²ΠΎΡΠΏΡ€ΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΠΌΠΎΡΡ‚ΡŒ ΠΌΠ΅ΠΆΠ΄Ρƒ Π½Π΅Π·Π½Π°ΠΊΠΎΠΌΡ‹ΠΌΠΈ Π΄Ρ€ΡƒΠ³ с Π΄Ρ€ΡƒΠ³ΠΎΠΌ ΠΏΠ°Ρ‚ΠΎΠ»ΠΎΠ³Π°ΠΌΠΈ Π±Ρ‹Π»Π° Π½Π°ΠΌΠ½ΠΎΠ³ΠΎ большС, Ρ‡Π΅ΠΌ Π² Π³Ρ€ΡƒΠΏΠΏΠ°Ρ… ΠΏΠ°Ρ‚ΠΎΠ»ΠΎΠ³ΠΎΠ², ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ ΡƒΡ‡ΠΈΠ»ΠΈΡΡŒ ΠΈΠ»ΠΈ Ρ€Π°Π±ΠΎΡ‚Π°Π»ΠΈ вмСстС. Π’Π°ΠΆΠ½ΠΎΠΉ Π·Π°Π΄Π°Ρ‡Π΅ΠΉ классификации Π’ΠžΠ— 2004 Π³. Π±Ρ‹Π»ΠΎ ΠΏΡ€Π΅Π΄ΠΎΡΡ‚Π°Π²ΠΈΡ‚ΡŒ Π΄Π΅Ρ‚Π°Π»ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠ΅ объяснСниС гистологичСских ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠ΅Π² для ΠΊΠ°ΠΆΠ΄ΠΎΠΉ диагностичСской ΠΊΠ°Ρ‚Π΅Π³ΠΎΡ€ΠΈΠΈ ΠΈ, Ρ‚Π°ΠΊΠΈΠΌ ΠΎΠ±Ρ€Π°Π·ΠΎΠΌ, ΡƒΠ»ΡƒΡ‡ΡˆΠΈΡ‚ΡŒ Π²ΠΎΡΠΏΡ€ΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΠΌΠΎΡΡ‚ΡŒ ΠΌΠ΅ΠΆΠ΄Ρƒ Ρ€Π°Π·Π½Ρ‹ΠΌΠΈ ΠΏΠ°Ρ‚ΠΎΠ»ΠΎΠ³Π°ΠΌΠΈ. Однако ΡƒΠ»ΡƒΡ‡ΡˆΠ΅Π½ΠΈΡ воспроизводимости ΠΌΠ΅ΠΆΠ΄Ρƒ ΠΏΠ°Ρ‚ΠΎΠ»ΠΎΠ³Π°ΠΌΠΈ ΠΏΠΎ ΡΡ€Π°Π²Π½Π΅Π½ΠΈΡŽ с классификациСй Π’ΠžΠ— 1973 Π³. Π½Π΅ зафиксировано. Π‘ΠΎΠ»Π΅Π΅ Ρ‚ΠΎΠ³ΠΎ, срСди ΠΏΠ°Ρ‚ΠΎΠ»ΠΎΠ³ΠΎΠ² ΠΎΡ‚ΠΌΠ΅Ρ‡Π΅Π½Π° Π»ΡƒΡ‡ΡˆΠ°Ρ Π²ΠΎΡΠΏΡ€ΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΠΌΠΎΡΡ‚ΡŒ классификации Π’ΠžΠ— 1973 Π³. ΠΏΠΎ ΡΡ€Π°Π²Π½Π΅Π½ΠΈΡŽ с классификациями 1999 ΠΈ 2004 Π³Π³. Π’ΠΎΡΠΏΡ€ΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΠΌΠΎΡΡ‚ΡŒ с Π΄ΠΈΠ°Π³Π½ΠΎΠ·ΠΎΠΌ папиллярной ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ с Π½ΠΈΠ·ΠΊΠΈΠΌ ΠΏΠΎΡ‚Π΅Π½Ρ†ΠΈΠ°Π»ΠΎΠΌ злокачСствСнности составила всСго 48 %. Π’ Ρ‚ΠΎ ΠΆΠ΅ врСмя Π²ΠΎΡΠΏΡ€ΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΠΌΠΎΡΡ‚ΡŒ классификации Π’ΠžΠ— 1973 Π³. ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ Ρ‚Π°ΠΊΠΆΠ΅ ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΠ°Ρ‚ΠΈΡ‡Π½Π°. ΠΠ°ΠΈΠ±ΠΎΠ»ΡŒΡˆΡƒΡŽ ΠΊΡ€ΠΈΡ‚ΠΈΠΊΡƒ этой систСмы Π²Ρ‹Π·Ρ‹Π²Π°Π΅Ρ‚ Π½Π΅ΠΎΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½Π½ΠΎΡΡ‚ΡŒ ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠ΅Π² диагностики Π² Ρ€Π°Π·Π΄Π΅Π»Π΅Π½ΠΈΠΈ 3 стСпСнСй ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΡ‹.Π’Ρ‹Π²ΠΎΠ΄Ρ‹. Бтандартизация систСмы стадирования повСрхностного Ρ€Π°ΠΊΠ° ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря позволяСт Π²Π°Π»ΠΈΠ΄ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Ρ‚ΡŒ сравнСниС Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚ΠΎΠ² лСчСния Π² Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ…. Π’Π²Π΅Π΄Π΅Π½ΠΈΠ΅ классификации 2004 Π³. являСтся ΠΏΠ΅Ρ€Π²Ρ‹ΠΌ шагом Π² стандартизации лСчСния ΠΈ Ρ€Π΅ΠΆΠΈΠΌΠΎΠ² наблюдСния, ΠΎΠ΄Π½Π°ΠΊΠΎ всС ΠΏΡ€Π΅Π΄Π»ΠΎΠΆΠ΅Π½Π½Ρ‹Π΅ Π’ΠžΠ— классификации ΠΈΠΌΠ΅ΡŽΡ‚ нСдостатки, обусловлСнныС Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠΉ Π³Π΅Ρ‚Π΅Ρ€ΠΎΠ³Π΅Π½Π½ΠΎΡΡ‚ΡŒΡŽ срСди папиллярных ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ. Π—Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½Π°Ρ ΠΌΠ΅ΠΆΠ½Π°Π±Π»ΡŽΠ΄Π°Ρ‚Π΅Π»ΡŒΠ½Π°Ρ Π²ΠΎΡΠΏΡ€ΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΠΌΠΎΡΡ‚ΡŒ ΠΌΠ΅ΠΆΠ΄Ρƒ папиллярной ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΠΎΠΏΡƒΡ…ΠΎΠ»ΡŒΡŽ с Π½ΠΈΠ·ΠΊΠΈΠΌ ΠΏΠΎΡ‚Π΅Π½Ρ†ΠΈΠ°Π»ΠΎΠΌ злокачСствСнности ΠΈ папиллярной ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΠΎΠΉ Π½ΠΈΠ·ΠΊΠΎΠΉ стСпСни злокачСствСнности ΡƒΠΊΠ°Π·Ρ‹Π²Π°Π΅Ρ‚ Π½Π° Π½Π΅Ρ†Π΅Π»Π΅ΡΠΎΠΎΠ±Ρ€Π°Π·Π½ΠΎΡΡ‚ΡŒ выдСлСния ΠΎΡ‚Π΄Π΅Π»ΡŒΠ½ΠΎΠΉ диагностичСской ΠΊΠ°Ρ‚Π΅Π³ΠΎΡ€ΠΈΠΈ папиллярной ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ с Π½ΠΈΠ·ΠΊΠΈΠΌ ΠΏΠΎΡ‚Π΅Π½Ρ†ΠΈΠ°Π»ΠΎΠΌ злокачСствСнности

    ЭкспрСссия Ρ€53 Π² повСрхностных ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΠ°Ρ… ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря – нСзависимый Ρ„Π°ΠΊΡ‚ΠΎΡ€ ΠΏΡ€ΠΎΠ³Π½ΠΎΠ·Π°

    Get PDF
    Purpose. Determination the role of the p53 expression as a prognostic factor in the development of superficial urothelial bladder carcinoma.Materials and methods. Medical histories of 72 patients (11 women and 61 men) with diagnosed primary superficial urothelial carcinomaΒ of the bladder I and II grade were retrospectively analyzed. All patients were undergone a repeated transurethral resection was performedΒ in 6 weeks after the first operation. In the case of the absence of residual tumor, cystoscopy was performed every 3 months during the first yearΒ then every 3–6 months during next 5 years. The average time of follow-up was 43.2 months. According to the standard protocol an immunohistochemicalΒ study with detection of p53 was carried out on 72 sections of formalin-fixed and paraffin-embedded tumor fragments. p53 expressionΒ was also determined in 10 histologically unchanged fragments of the bladder mucosa.Results. Depending on the percent of nuclei with p53 expression, two groups were identified. The first group included 40 tumor samples (55.5 %)Β with p53 expression less than 20 % and 17 tumor samples (23.6 %) without p53 expression. The second group included 15 tumor samplesΒ (20.9 %) with p53 expression more than 20 % (4 patients – 20–40 %, 8 patients – 40–60 %, 3 patients – 60–80 %). Ρ€53 expression wasΒ not determined in the all 10 samples of normal bladder tissue. During follow-up period 1 of 57 patients of the first group has a disease progressionΒ comparing with 13 of 15 patients in the second group. Patients of the both group were similar in respect with clinical characteristics.Β The mean time to disease progression was 17.3 months.Conclusion. Results of the current study shows that p53 immunohistochemical marker is a prognostic factor in the development of superficialΒ urothelial bladder carcinoma.Π’Π²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠŸΡ€ΠΈΠΌΠ΅Ρ€Π½ΠΎ 80 % ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎ диагностируСмых ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌ ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря ΡΠ²Π»ΡΡŽΡ‚ΡΡ повСрхностными. ΠŸΡ€ΠΈΒ ΡΡ‚ΠΎΠΌ Ρƒ 10–20 % ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎ выявляСмым повСрхностным ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½Ρ‹ΠΌ Ρ€Π°ΠΊΠΎΠΌ впослСдствии развиваСтся ΠΌΡ‹ΡˆΠ΅Ρ‡Π½ΠΎ-ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΠΎΠ΅ ΠΈ мСтастатичСскоС ΠΏΠΎΡ€Π°ΠΆΠ΅Π½ΠΈΠ΅. Π’ связи с этим Π²Π°ΠΆΠ½ΠΎΠΉ являСтся идСнтификация прогностичСских Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΎΠ², ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ ΠΌΠΎΠ³Π»ΠΈ Π±Ρ‹ Π²Ρ‹Π΄Π΅Π»ΠΈΡ‚ΡŒ Π³Ρ€ΡƒΠΏΠΏΡƒ повСрхностных ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ с Π±ΠΎΠ»Π΅Π΅ высоким ΠΏΠΎΡ‚Π΅Π½Ρ†ΠΈΠ°Π»ΠΎΠΌ агрСссивности.ЦСль исслСдования – ΠΎΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Ρ€ΠΎΠ»ΠΈ экспрСссии Ρ€53 ΠΊΠ°ΠΊ Ρ„Π°ΠΊΡ‚ΠΎΡ€Π° ΠΏΡ€ΠΎΠ³Π½ΠΎΠ·Π° Π² Ρ€Π°Π·Π²ΠΈΡ‚ΠΈΠΈ повСрхностных ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΒ ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. РСтроспСктивно ΠΏΡ€ΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π½Ρ‹ 72 истории Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² (11 ΠΆΠ΅Π½Ρ‰ΠΈΠ½ ΠΈ 61 ΠΌΡƒΠΆΡ‡ΠΈΠ½Ρ‹) с пСрвично диагностированным повСрхностным ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½Ρ‹ΠΌ Ρ€Π°ΠΊΠΎΠΌ ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря I ΠΈ II стСпСнСй злокачСствСнности. ВсСм ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π°ΠΌ Π±Ρ‹Π»Π°Β ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½Π° повторная Ρ‚Ρ€Π°Π½ΡΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½Π°Ρ рСзСкция Ρ‡Π΅Ρ€Π΅Π· 6 Π½Π΅Π΄ послС 1-ΠΉ ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΈ. ΠŸΡ€ΠΈ отсутствии остаточной ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ пациСнтам выполняли цистоскопичСскоС исслСдованиС ΠΊΠ°ΠΆΠ΄Ρ‹Π΅ 3 мСс Π² Ρ‚Π΅Ρ‡Π΅Π½ΠΈΠ΅ 1-Π³ΠΎ Π³ΠΎΠ΄Π° послС Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²Π° ΠΈ ΠΊΠ°ΠΆΠ΄Ρ‹Π΅ 3–6 мСс Π² ΠΏΠΎΡΠ»Π΅Π΄ΡƒΡŽΡ‰Π΅ΠΌ.Β Π‘Ρ€Π΅Π΄Π½Π΅Π΅ врСмя наблюдСния составило 43,2 мСс. Π˜ΠΌΠΌΡƒΠ½ΠΎΠ³ΠΈΡΡ‚ΠΎΡ…ΠΈΠΌΠΈΡ‡Π΅ΡΠΊΠΎΠ΅ исслСдованиС с ΠΎΠ½ΠΊΠΎΠΏΡ€ΠΎΡ‚Π΅ΠΈΠ½ΠΎΠΌ Ρ€53 Π±Ρ‹Π»ΠΎ ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΏΠΎ стандартному ΠΏΡ€ΠΎΡ‚ΠΎΠΊΠΎΠ»Ρƒ Π½Π° 72 срСзах повСрхностных зафиксированных Ρ„ΠΎΡ€ΠΌΠ°Π»ΠΈΠ½ΠΎΠΌ ΠΈ Π·Π°Π»ΠΈΡ‚Ρ‹Ρ… Π² ΠΏΠ°Ρ€Π°Ρ„ΠΈΠ½ Ρ„Ρ€Π°Π³ΠΌΠ΅Π½Ρ‚ΠΎΠ² ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ. ЭкспрСссия Ρ€53 Ρ‚Π°ΠΊΠΆΠ΅ Π±Ρ‹Π»Π° ΠΎΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½Π° Π² 10 гистологичСски Π½Π΅ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½Ρ‹Ρ… Ρ„Ρ€Π°Π³ΠΌΠ΅Π½Ρ‚Π°Ρ… слизистой ΠΎΠ±ΠΎΠ»ΠΎΡ‡ΠΊΠΈ ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. Π’ зависимости ΠΎΡ‚ ΠΏΡ€ΠΎΡ†Π΅Π½Ρ‚Π° ядСр с экспрСссиСй Ρ€53 Π±Ρ‹Π»ΠΈ Π²Ρ‹Π΄Π΅Π»Π΅Π½Ρ‹ 2 Π³Ρ€ΡƒΠΏΠΏΡ‹: 1-ю составили 40 (55,5 %) ΠΎΠ±Ρ€Π°Π·Ρ†ΠΎΠ²Β ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ с экспрСссиСй Ρ€53 &lt; 20 % ΠΈ 17 (23,6 %) ΠΎΠ±Ρ€Π°Π·Ρ†ΠΎΠ² Π±Π΅Π· экспрСссии Ρ€53; 2-ю – 15 (20,9 %) ΠΎΠ±Ρ€Π°Π·Ρ†ΠΎΠ² с экспрСссиСй Ρ€53 &gt; 20 %Β (4 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π° – 20–40 %, 8 – 40–60 %, 3 – 60–80 %). Π’ Π½ΠΎΡ€ΠΌΠ°Π»ΡŒΠ½ΠΎΠΉ Ρ‚ΠΊΠ°Π½ΠΈ ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря Π²ΠΎ всСх 10 ΠΎΠ±Ρ€Π°Π·Ρ†Π°Ρ… экспрСссия Ρ€53Β Π½Π΅ ΠΎΠΏΡ€Π΅Π΄Π΅Π»ΡΠ»Π°ΡΡŒ. Π—Π° врСмя наблюдСния Ρƒ 1 ΠΈΠ· 57 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² 1-ΠΉ Π³Ρ€ΡƒΠΏΠΏΡ‹ Π±Ρ‹Π»ΠΎ ΠΎΡ‚ΠΌΠ΅Ρ‡Π΅Π½ΠΎ прогрСссированиС заболСвания, Π²ΠΎ 2-ΠΉ Π³Ρ€ΡƒΠΏΠΏΠ΅Β ΠΈΡ… число достигало 13 ΠΈΠ· 15. ΠŸΠ°Ρ†ΠΈΠ΅Π½Ρ‚Ρ‹ Π³Ρ€ΡƒΠΏΠΏ сравнСния ΠΎΠ΄ΠΈΠ½Π°ΠΊΠΎΠ²Ρ‹ ΠΏΠΎ клиничСским характСристикам. Π‘Ρ€Π΅Π΄Π½Π΅Π΅ врСмя Π΄ΠΎ прогрСссирования заболСвания составило 17,3 мСс.Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ настоящСго исслСдования Π΄ΠΎΠΊΠ°Π·Ρ‹Π²Π°ΡŽΡ‚, Ρ‡Ρ‚ΠΎ ΠΎΠ½ΠΊΠΎΠΌΠ°Ρ€ΠΊΠ΅Ρ€ p53 являСтся Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΎΠΌ ΠΏΡ€ΠΎΠ³Π½ΠΎΠ·Π° Π² развитии повСрхностных ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌ ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря

    ΠšΠΈΡΡ‚ΠΎΠ·Π½Ρ‹ΠΉ ΠΈ ТСлСзистый цистит, коррСляция с ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½Ρ‹ΠΌ Ρ€Π°ΠΊΠΎΠΌ ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря

    Get PDF
    Background. Cystic-glandular cysititis is defined as cystic formation of the urothelial nests which may be associated with inflammatory conditions as well as neoplastic processes.Objective – to establish a relationship between cystic-glandular cysititis and bladder cancer.Materials and methods. We conducted a retrospective study using data of 52 patients who’d been diagnosed with cystic-glandular cysititis of common or intestinal type in the period between 2006 and 2014. The patients’ information regarding age, gender, type of histological material (biopsy or transurethral resection of bladder), urological anamnesis has been analyzed. Follow-up duration included cystoscopy performance with bladder biopsy and varied from 1 to 8 years.Results. Patients suffering from diagnosed cystic-glandular cystitis were between the ages of 27 and 89 years old, with a higher prevalence rate, 2:1, in men to women. Intestinal metaplasia was revealed in 7 (14 %) out of 52 patients. Thorough study of the urological anamnesis revealed 50 (96 %) cases of chronic bladder inflammation. Concurrent cancer was diagnosed in 6 (12 %) cases: 4 patients with urothelial carcinoma and 2 – with intestinal type adenocarcinoma. Follow-up of the remained 46 patients revealed the development of urothelial carcinoma in 1 patient which happened 6 months after his primary biopsy. By the way, this patient has already had upper urinary tract urothelial carcinoma in his anamnesis.Conclusions. Study results show that there is a relatively frequent coexistence of cystic-glandular cystitis and bladder cancer. However, longterm follow-up of patients with cystic-glandular cystitis don’t allow us to consider this pathology as a preneoplastic.Π’Π²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠšΠΈΡΡ‚ΠΎΠ·Π½ΠΎ-ТСлСзистый цистит прСдставляСт собой кистозно Ρ€Π°ΡΡˆΠΈΡ€Π΅Π½Π½Ρ‹Π΅ Β«Π³Π½Π΅Π·Π΄Π°Β» уротСлия, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Π΅ ΠΌΠΎΠ³ΡƒΡ‚ Π²ΡΡ‚Ρ€Π΅Ρ‡Π°Ρ‚ΡŒΡΡ ΠΊΠ°ΠΊ ΠΏΡ€ΠΈ Π²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹Ρ… состояниях, Ρ‚Π°ΠΊ ΠΈ ΠΏΡ€ΠΈ ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅Π²Ρ‹Ρ… процСссах.ЦСль исслСдования – ΠΎΠΏΡ€Π΅Π΄Π΅Π»ΠΈΡ‚ΡŒ Π½Π°Π»ΠΈΡ‡ΠΈΠ΅ взаимосвязи ΠΌΠ΅ΠΆΠ΄Ρƒ кистозно-ТСлСзистым циститом ΠΈ ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΠΎΠΉ ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. ΠŸΡ€ΠΎΠ²Π΅Π΄Π΅Π½ΠΎ рСтроспСктивноС исслСдованиС 52 историй Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ², Ρƒ ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ… Π² ΠΏΠ΅Ρ€ΠΈΠΎΠ΄ с 2006 ΠΏΠΎ 2014 Π³. Π±Ρ‹Π» диагностирован кистозно-ТСлСзистый цистит с ΠΊΠΈΡˆΠ΅Ρ‡Π½ΠΎΠΉ ΠΌΠ΅Ρ‚Π°ΠΏΠ»Π°Π·ΠΈΠ΅ΠΉ ΠΈΠ»ΠΈ Π±Π΅Π· Ρ‚Π°ΠΊΠΎΠ²ΠΎΠΉ. ΠŸΡ€ΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π½Ρ‹ ΡΠ»Π΅Π΄ΡƒΡŽΡ‰ΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»ΠΈ: возраст, ΠΏΠΎΠ» ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π°, Ρ‚ΠΈΠΏ исслСдованного ΠΌΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Π° (биопсия ΠΈΠ»ΠΈ Ρ‚Ρ€Π°Π½ΡΡƒΡ€Π΅Ρ‚Ρ€Π°Π»ΡŒΠ½Π°Ρ рСзСкция ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря), урологичСский Π°Π½Π°ΠΌΠ½Π΅Π· ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ². ДинамичСскоС наблюдСниС Π²ΠΊΠ»ΡŽΡ‡Π°Π»ΠΎ Π²Ρ‹ΠΏΠΎΠ»Π½Π΅Π½ΠΈΠ΅ цистоскопичСского исслСдования с биопсиСй ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря ΠΈ составило ΠΎΡ‚ 1 Π΄ΠΎ 8 Π»Π΅Ρ‚.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. Возраст ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с диагностированным кистозно-ТСлСзистым циститом Π²Π°Ρ€ΡŒΠΈΡ€ΠΎΠ²Π°Π» ΠΎΡ‚ 27 Π΄ΠΎ 89 Π»Π΅Ρ‚, ΡΠΎΠΎΡ‚Π½ΠΎΡˆΠ΅Π½ΠΈΠ΅ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² муТского ΠΈ ТСнского ΠΏΠΎΠ»Π° составляло 2:1. Из 52 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² ΠΊΠΈΡˆΠ΅Ρ‡Π½Π°Ρ мСтаплазия Π±Ρ‹Π»Π° диагностирована Ρƒ 7 (14 %), Ρƒ 50 (96 %) Π² Π°Π½Π°ΠΌΠ½Π΅Π·Π΅ ΠΎΡ‚ΠΌΠ΅Ρ‡Π΅Π½ΠΎ хроничСскоС воспалСниС ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря. НаличиС ΡΠΎΠΏΡƒΡ‚ΡΡ‚Π²ΡƒΡŽΡ‰Π΅ΠΉ ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΡ‹ диагностировано Π² 6 (12 %) случаях: Π² 4 – ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½Π°Ρ ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΠ° ΠΈ Π² 2 – ТСлСзистая Π°Π΄Π΅Π½ΠΎΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΠ° ΠΊΠΈΡˆΠ΅Ρ‡Π½ΠΎΠ³ΠΎ Ρ‚ΠΈΠΏΠ°. ДинамичСскоС наблюдСниС ΠΎΡΡ‚Π°Π²ΡˆΠΈΡ…ΡΡ 46 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΎ Ρ€Π°Π·Π²ΠΈΡ‚ΠΈΠ΅ ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΡ‹ Ρ‚ΠΎΠ»ΡŒΠΊΠΎ Ρƒ 1 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π° Ρ‡Π΅Ρ€Π΅Π· 6 мСс послС ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎΠΉ биопсии, ΠΏΡ€ΠΈ этом Π² Π°Π½Π°ΠΌΠ½Π΅Π·Π΅ Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π° Π±Ρ‹Π»Π° ΡƒΡ€ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½Π°Ρ ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΠ° Π²Π΅Ρ€Ρ…Π½ΠΈΡ… ΠΌΠΎΡ‡Π΅Π²Ρ‹Ρ… ΠΏΡƒΡ‚Π΅ΠΉ.Π’Ρ‹Π²ΠΎΠ΄Ρ‹. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ исслСдования ΠΏΠΎΠΊΠ°Π·Ρ‹Π²Π°ΡŽΡ‚ довольно частоС сосущСствованиС кистозно-ТСлСзистого цистита ΠΈ ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΡ‹ ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря, Ρ‚Π΅ΠΌ Π½Π΅ ΠΌΠ΅Π½Π΅Π΅ Π΄Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ΅ наблюдСниС Π·Π° ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π°ΠΌΠΈ с кистозно-ТСлСзистым циститом Π½Π΅ позволяСт Ρ€Π°ΡΡΠΌΠ°Ρ‚Ρ€ΠΈΠ²Π°Ρ‚ΡŒ это состояниС ΠΊΠ°ΠΊ ΠΏΡ€Π΅Π΄Ρ€Π°ΠΊΠΎΠ²ΠΎΠ΅
    • …
    corecore